R&D channel feed

Med­i­ci­No­va flops in PhII metham­phet­a­mine de­pen­dence tri­al, stock slips

8 years ago

Faced with fresh con­cerns about Hem­li­bra’s safe­ty, Roche spells out what it knows about 5 deaths

8 years ago

Tiny Redx slammed af­ter first pa­tient is hit by ad­verse events, forc­ing a halt to can­cer drug study

8 years ago

Blue­bird whis­tles up a co-de­vel­op­ment/co-pro­mo­tion pact with Cel­gene on bb2121 CAR-T

8 years ago

Ele­phants can't jump? IDEA's Mike Rea says some Big Phar­ma play­ers are crush­ing old be­liefs

8 years ago
Special
Biotech Voices

He­mo­phil­ia groups warned of 5 deaths among pa­tients tak­ing Roche’s big new block­buster Hem­li­bra

8 years ago

Lies, damn lies and sta­tis­tics: A Stan­ford wiz says P<0.05 of­fers de­cep­tive ev­i­dence of bio­phar­mas' drug claims

8 years ago
Bioregnum
Opinion

Anap­tys­Bio clears an ear­ly hur­dle in low-stress PoC study for peanut al­ler­gy med -- big ques­tions go unan­swered

8 years ago

FDA hands a ‘break­through’ des­ig­na­tion to Seat­tle Ge­net­ics’ piv­otal-stage can­cer drug en­for­tum­ab

8 years ago

Bio­haven touts a pair of PhI­II wins for mi­graine pill, but shares ric­o­chet off of weak da­ta

8 years ago

Pro­tag­o­nist aborts lead ul­cer­a­tive col­i­tis pro­gram af­ter drug fiz­zles in PhI­Ib, stock craters

8 years ago

Gain­ing steam in PD-1/L1 race, Roche re­ports pos­i­tive PhI­II OS da­ta on Tecen­triq com­bo in NSCLC

8 years ago

Failed again: Sanofi's Abl­ynx re­ports PhII lu­pus flop

8 years ago

Beat­ing out mar­ket lead­ers in PhII, an­tibi­ot­ic-mak­er Al­le­cra read­ies for Phase III tri­als

8 years ago

GSK drops out of $20B race for Pfiz­er's con­sumer health unit — shares surge

8 years ago

Poised for an FDA pitch, No­var­tis lays out all its PhI­II cards on MS drug sipon­i­mod

8 years ago

Ab­b­Vie shares tank on Ro­va-T flop, sud­den re­treat from ac­cel­er­at­ed ap­proval pitch

8 years ago

Cash­ing in on PhII tri­al suc­cess, Are­na to raise $353M to fu­el PhI­II etrasi­mod/ra­linepag tri­als

8 years ago

12 block­busters: The surg­ing list of $1B-plus drugs rolling out on the mar­ket this year might sur­prise you

8 years ago
Special

As­traZeneca touts a fresh cut of Farx­i­ga da­ta tar­get­ing di­a­betes pa­tients with chron­ic kid­ney dis­ease

8 years ago

Leapfrog­ging ri­vals, Roche's Tecen­triq plus chemo nabs PFS end­point in front­line lung can­cer seg­ment

8 years ago

Are­na bounces back. Stock soars on ozan­i­mod ri­val's PhII suc­cess

8 years ago

No­vo Nordisk's new obe­si­ty da­ta tip the scales in semaglu­tide's fa­vor as land­mark piv­otal pro­gram looms

8 years ago

Cidara touts 'pos­i­tive' PhII tri­al da­ta for an­ti­fun­gal, shares yo-yo on the news

8 years ago
First page Previous page 276277278279280281282 Next page Last page
A service from the Financial Times